Table 1. Prospective trials with EPP in a multimodality paradigm.
| 1st Therapy | 2nd Therapy | Radiation | Median OS (months) | Resection Rate | Complete all therapy | Reference |
|---|---|---|---|---|---|---|
| Chemo 67/77 (87%) | EPP 57/64 (89%) | 40/44 (91%) | 17 | 74% | 52% | Krug (5) |
| Chemo 58/61 (95%) | EPP 45/61 (74%) | 24/36 (67%) | 20 | 74% | 39% | Weder (6) |
| Chemo 55/58 (95%) | EPP 42/58 (72%) | 37/38 (97%) | 18 | 72% | 63% | Van Schil (7) |
| EPP 44/54 (81%) | Chemo 31/42 (74%) | 31/42 (74%) | 20 | 81% | 57% | Pagan (8) |
| Chemo 10/21 (48%) | EPP 9/10 (90%) | 7/8 (88%) | 19 | 43% | 33% | Flores (9) |
| Chemo 20/21 (95%) | EPP 17/21 (81%) | 13/15 (87%) | 26 | 81% | 62% | Rea (10) |
| EPP 16/20 (80%) | Chemo 12/12 (100%) | 12/16 (75%) | 17 | 80% | 60% | Batirel (11) |
| Chemo 18/19 (95%) | EPP 16/19 (84%) | 6/13 (46%) | 23 | 84% | 32% | Weder (12) |